Pedro Valencia, VP, asset strategy, leadership, oncology, AbbVie, outlines how the company is accelerating development across ...

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to DATROWAY® (datopotamab deruxtecan-dlnk) for ...

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for ...

Partial nephrectomy preserves renal function better than radical nephrectomy for complex tumors, especially in younger ...

The company said the therapy is the first allogenic therapy developed with its Tmod technology to be tested in humans.

The Food and Drug Administration (FDA) has granted accelerated approval to Datroway ® (datopotamab deruxtecan-dlnk) for adults with locally advanced or metastatic epidermal growth factor receptor ...

The FDA has granted accelerated approval to datopotamab deruxtecan (Datroway) for adults with locally advanced or metastatic non-small cell lung cancer that carries an EGFR mutation and has progressed ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat ...

The FDA has blessed AstraZeneca and Daiichi Sankyo’s Datroway to treat patients with locally advanced or metastatic epidermal ...

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said Datroway has secured US Food & Drug Administration approval for use in adult patients with previously treated advanced ...